1.	Analysis of Pharmacodynamic Changes With AUY922A, an HSP90 Inhibitor Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis Status: Active Age: 16 and over Sponsor: Other Protocol IDs: CCR3113, NCT01024283
2.	A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 20 to 75 Sponsor: Other Protocol IDs: T2211, NCT01389583
3.	Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: SCRI GI 148, NCT01404650
4.	Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: DDP-922, NCT01484860
5.	A Study of the HSP90 Inhibitor AUY922 Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2011-0467, NCT01485536
6.	An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAUY922A2207, 2012-001050-25, NCT01646125
7.	HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 12-076, NCT01668173
8.	AUY922 for Advanced ALK-positive NSCLC Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 12-458, NCT01752400
9.	Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CAUY922AUS06T, NCT01294826
10.	PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CBYL719X2103, 2011-005978-40, NCT01613950
11.	Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CLDK378X2102, 2012-004632-29, NCT01772797
12.	Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI, Other Protocol IDs: L-05, NCI-2013-00410, NCT01784640